Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CTSA | P10619 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7045941 | 0.69 | CTSA (0.46) | ALDH1A1CTSAACHEKDM4EPOLB | |
| SCHEMBL11737808 | 0.68 | CTSA (0.41) | ALDH1A1CTSAACHEKDM4E | |
| SCHEMBL8052562 | 0.67 | CTSA (0.43) | ALDH1A1CTSAACHEKDM4EPOLB | |
| SCHEMBL11597211 | 0.67 | — | — | |
| SCHEMBL18486500 | 0.67 | MMP1 (0.50) | ALDH1A1CTSAACHEKDM4EPOLB | |
| SCHEMBL8050098 | 0.65 | LMNA (0.41) | ALDH1A1 | |
| SCHEMBL11472592 | 0.65 | CTSA (0.37) | ALDH1A1CTSAACHEKDM4EPOLB | |
| SCHEMBL19141847 | 0.64 | — | — | |
| SCHEMBL4611582 | 0.63 | ALDH1A1 (0.34) | ALDH1A1CTSAACHE | |
| SCHEMBL10395342 | 0.62 | CTSA (0.43) | ALDH1A1CTSAACHEKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8993544-B2 | Carbamoylphosphonates as inhibitors and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2015-03-31 | — | — | US | disclosed |
| US-8993544-B2 | Carbamoylphosphonates as inhibitors and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2015-03-31 | — | — | US | disclosed |
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2012-02-09 | — | — | US | disclosed |
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | MMP9, MMP26, MMP25 | ALDH1A1 2720/4885CTSA 51/4885ACHE 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.